Skip to main content

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

Terminated · Phase 2 · NCT05349721

Conditions: Amyotrophic Lateral Sclerosis

At a glance

Research payments reported, 2025
$284,002
U.S. investigators named
13
Sites paid
13
Planned or actual enrollment
336

About the trial

Sponsor
PTC Therapeutics
Tested
PTC857 (drug), Placebo (drug)
Dates
Started 2022-05-15; completion 2025-01-30
Results posted
Yes

This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.

From ClinicalTrials.gov, last updated 2025-08-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ptc Therapeutics, Inc. reported $284,002 in research payments for this study in 2025 (47 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.